Zydus Lifesciences Limited
ZYDUSLIFE
株式のランク
#1758
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
株価
$12.04
時価総額
$12.01B
変化（1日）
-2.15%
変化（1年）
6.00%
国
IN
取引 Zydus Lifesciences Limited (ZYDUSLIFE)
カテゴリー
Healthcare
Zydus Lifesciences Limited（ZYDUSLIFE）の収益
Jun 2026 時点の収益 TTM: $3.16B
Zydus Lifesciences Limited の最新の財務報告によると、現在の収益 (TTM) は $3.16B です。2025 年には $2.72B の収益があり、これは 2024 年の $2.34B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Zydus Lifesciences Limited の収益履歴（2004 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $3.16B | 16.11% |
| 2025 | $2.72B | 15.92% |
| 2024 | $2.34B | 11.77% |
| 2023 | $2.10B | 5.37% |
| 2022 | $1.99B | 1.17% |
| 2021 | $1.97B | 4.00% |
| 2020 | $1.89B | -0.21% |
| 2019 | $1.90B | 3.69% |
| 2018 | $1.83B | 26.46% |
| 2017 | $1.45B | 1.62% |
| 2016 | $1.42B | 2.63% |
| 2015 | $1.39B | 15.37% |
| 2014 | $1.20B | 3.47% |
| 2013 | $1.16B | 15.71% |
| 2012 | $1.00B | 0.20% |
| 2011 | $1.00B | 22.04% |
| 2010 | $820.89M | 45.59% |
| 2009 | $563.82M | -0.43% |
| 2008 | $566.27M | 37.48% |
| 2007 | $411.90M | 26.93% |
| 2006 | $324.50M | 14.00% |
| 2005 | $284.66M | 3.30% |
| 2004 | $275.56M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 109.54% |
IN
|
